Class information for:
Level 1: CD20//OFATUMUMAB//OBINUTUZUMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
10008 1099 48.2 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
118 3       EPSTEIN BARR VIRUS//LYMPHOMA//HODGKINS DISEASE 69002
109 2             CHRONIC LYMPHOCYTIC LEUKEMIA//HODGKINS DISEASE//MANTLE CELL LYMPHOMA 25223
10008 1                   CD20//OFATUMUMAB//OBINUTUZUMAB 1099

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CD20 authKW 1053564 13% 26% 146
2 OFATUMUMAB authKW 339911 3% 37% 33
3 OBINUTUZUMAB authKW 292304 2% 48% 22
4 RITUXIMAB authKW 290633 19% 5% 209
5 ADCC authKW 257940 6% 15% 64
6 RITUXIMAB RESISTANCE authKW 136133 1% 70% 7
7 CD20 EXPRESSION authKW 125021 1% 75% 6
8 GA101 authKW 115761 0% 83% 5
9 COMPLEMENT DEPENDENT CYTOTOXICITY authKW 87783 1% 20% 16
10 EA3853 address 83349 0% 100% 3

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Hematology 7096 25% 0% 273
2 Oncology 5167 36% 0% 397
3 Immunology 3074 26% 0% 289
4 Medicine, Research & Experimental 454 9% 0% 95
5 Rheumatology 76 2% 0% 20
6 Pharmacology & Pharmacy 67 7% 0% 80
7 Cell Biology 31 5% 0% 54
8 Biochemical Research Methods 29 3% 0% 30
9 Pathology 29 2% 0% 24
10 Biotechnology & Applied Microbiology 28 4% 0% 41

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EA3853 83349 0% 100% 3
2 ANTIBODY VACCINE GRP 77299 1% 35% 8
3 MOL GENET IMMUNOL 60791 2% 12% 18
4 STEM CELL TRANSPLANTAT IMMUNOTHER Y 59817 1% 15% 14
5 CELLULAR GENE THER Y G LANZANI 57876 0% 42% 5
6 TENOVUS CANC SCI 57876 0% 42% 5
7 LYMPHOMA TRANSLAT 55566 0% 100% 2
8 TARGETED THER Y GRPPATERSON CANC 55566 0% 100% 2
9 MOL IMMUNOHAEMATOL 55562 0% 50% 4
10 TENOVUS 54222 2% 11% 17

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MABS 16606 2% 3% 21
2 BLOOD 6767 8% 0% 92
3 CANCER IMMUNOLOGY RESEARCH 3944 1% 2% 8
4 CLINICAL CANCER RESEARCH 3735 4% 0% 45
5 JOURNAL OF IMMUNOLOGY 2834 7% 0% 75
6 LEUKEMIA & LYMPHOMA 2628 2% 0% 27
7 EXPERT OPINION ON BIOLOGICAL THERAPY 2582 1% 1% 14
8 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 1904 1% 1% 11
9 JOURNAL OF IMMUNOTHERAPY 1634 1% 1% 10
10 ONCOIMMUNOLOGY 1412 1% 1% 7

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 CD20 1053564 13% 26% 146 Search CD20 Search CD20
2 OFATUMUMAB 339911 3% 37% 33 Search OFATUMUMAB Search OFATUMUMAB
3 OBINUTUZUMAB 292304 2% 48% 22 Search OBINUTUZUMAB Search OBINUTUZUMAB
4 RITUXIMAB 290633 19% 5% 209 Search RITUXIMAB Search RITUXIMAB
5 ADCC 257940 6% 15% 64 Search ADCC Search ADCC
6 RITUXIMAB RESISTANCE 136133 1% 70% 7 Search RITUXIMAB+RESISTANCE Search RITUXIMAB+RESISTANCE
7 CD20 EXPRESSION 125021 1% 75% 6 Search CD20+EXPRESSION Search CD20+EXPRESSION
8 GA101 115761 0% 83% 5 Search GA101 Search GA101
9 COMPLEMENT DEPENDENT CYTOTOXICITY 87783 1% 20% 16 Search COMPLEMENT+DEPENDENT+CYTOTOXICITY Search COMPLEMENT+DEPENDENT+CYTOTOXICITY
10 HTM4 83349 0% 100% 3 Search HTM4 Search HTM4

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 WINIARSKA, M , GLODKOWSKA-MROWKA, E , BIL, J , GOLAB, J , (2011) MOLECULAR MECHANISMS OF THE ANTITUMOR EFFECTS OF ANTI-CD20 ANTIBODIES.FRONTIERS IN BIOSCIENCE-LANDMARK. VOL. 16. ISSUE . P. 277 -306 161 64% 23
2 PEREZ-CALLEJO, D , GONZALEZ-RINCON, J , SANCHEZ, A , PROVENCIO, M , SANCHEZ-BEATO, M , (2015) ACTION AND RESISTANCE OF MONOCLONAL CD20 ANTIBODIES THERAPY IN B-CELL NON-HODGKIN LYMPHOMAS.CANCER TREATMENT REVIEWS. VOL. 41. ISSUE 8. P. 680 -689 77 69% 8
3 BOROSS, P , LEUSEN, JHW , (2012) MECHANISMS OF ACTION OF CD20 ANTIBODIES.AMERICAN JOURNAL OF CANCER RESEARCH. VOL. 2. ISSUE 6. P. 676-690 77 68% 49
4 SEYFIZADEH, N , SEYFIZADEH, N , HASENKAMP, J , HUERTA-YEPEZ, S , (2016) A MOLECULAR PERSPECTIVE ON RITUXIMAB: A MONOCLONAL ANTIBODY FOR B CELL NON HODGKIN LYMPHOMA AND OTHER AFFECTIONS.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 97. ISSUE . P. 275 -290 87 48% 3
5 ILLIDGE, T , KLEIN, C , SEHN, LH , DAVIES, A , SALLES, G , CARTRON, G , (2015) OBINUTUZUMAB IN HEMATOLOGIC MALIGNANCIES: LESSONS LEARNED TO DATE.CANCER TREATMENT REVIEWS. VOL. 41. ISSUE 9. P. 784 -792 63 71% 6
6 REZVANI, AR , MALONEY, DG , (2011) RITUXIMAB RESISTANCE.BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. VOL. 24. ISSUE 2. P. 203 -216 63 68% 67
7 BEERS, SA , CHAN, CHT , FRENCH, RR , CRAGG, MS , GLENNIE, MJ , (2010) CD20 AS A TARGET FOR THERAPEUTIC TYPE I AND II MONOCLONAL ANTIBODIES.SEMINARS IN HEMATOLOGY. VOL. 47. ISSUE 2. P. 107 -114 49 88% 81
8 ABULAYHA, A , BREDAN, A , EL ENSHASY, H , DANIELS, I , (2014) RITUXIMAB: MODES OF ACTION, REMAINING DISPUTE AND FUTURE PERSPECTIVE.FUTURE ONCOLOGY. VOL. 10. ISSUE 15. P. 2481 -2492 64 69% 6
9 ALDUAIJ, W , ILLIDGE, TM , (2011) THE FUTURE OF ANTI-CD20 MONOCLONAL ANTIBODIES: ARE WE MAKING PROGRESS?.BLOOD. VOL. 117. ISSUE 11. P. 2993 -3001 61 63% 59
10 ROBAK, T , ROBAK, E , (2011) NEW ANTI-CD20 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF B-CELL LYMPHOID MALIGNANCIES.BIODRUGS. VOL. 25. ISSUE 1. P. 13 -25 50 81% 31

Classes with closest relation at Level 1


Rank Class id link
1 2691 FOLLICULAR LYMPHOMA//RADIOIMMUNOTHERAPY//RITUXIMAB
2 27270 U396//HUMAN LEUKOCYTE ANTIGEN II//IMMEDIATE EARLY PROTEINS IE
3 4824 AGALACTOSYL IGG//MABS//PROT ANALYT CHEM
4 3124 FC RECEPTOR//FC GAMMA RECEPTORS//FC GAMMA RECEPTOR
5 107 CHRONIC LYMPHOCYTIC LEUKEMIA//CLL//CHRONIC LYMPHOCYTIC LEUKAEMIA
6 9947 BISPECIFIC ANTIBODY//BISPECIFIC ANTIBODIES//CATUMAXOMAB
7 11281 ANTIBODY DRUG CONJUGATE//GEMTUZUMAB OZOGAMICIN//MYLOTARG
8 8410 CD59//CD55//CD46
9 14101 IDIOTYPE//IDIOTYPE VACCINATION//IDIOTYPE VACCINE
10 25537 PAX8//PAX5//PAX2

Go to start page